Results 71 to 80 of about 15,373 (177)
Cancer Science, EarlyView.Single CTC analysis revealed extensive inter‐ and intra‐patient heterogeneity of PI3K/AKT/PTEN pathway alterations in HR+/HER2− metastatic breast cancer, capturing both SNVs and CNAs, including PTEN loss‐of‐function events. Longitudinal CTC profiling also uncovered dynamic clonal evolution, highlighting its potential to complement tissue and ctDNA ...
Tania Rossi +10 more
wiley +1 more source
Fulvestrant revisited:Efficacy and safety of the 500-mg dose
, 2011 Postmenopausal women with hormone receptor-positive advanced breast cancer are candidates for endocrine therapy. As the disease will eventually progress in most patients, it is important to investigate agents with novel modes of action to reduce the ...
Howell, Anthony; id_orcid +3 more
core +1 more source
A guide to transcriptional cyclin‐dependent kinases in cancer
The FEBS Journal, EarlyView.Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin +2 more
wiley +1 more source
Functional grouping of fulvestrant resistance genes.
, 2014 Functional grouping of fulvestrant resistance genes.
Anker Hansen (214769) +7 more
core +1 more source
Epigenetic control of cellular plasticity in breast cancer progression
The FEBS Journal, EarlyView.Cancer cells undergo cell state transitions, termed plasticity, driving cancer progression and dictating therapeutic response. We define breast cancer plasticity into four interconnected processes: (1) breast cancer stem cell fates, (2) epithelial‐to‐mesenchymal transition, (3) maintenance of luminal identity, and (4) acquisition of therapeutic ...
Ellie J. Massey +2 more
wiley +1 more source
Periodontology 2000, EarlyView.Abstract Background Periodontal and peri‐implant diseases are multifactorial inflammatory conditions influenced by microbial, host, hormonal, genetic, and behavioral factors. Although sex‐based differences in immune and inflammatory responses are well recognized in medicine, the extent to which biologic sex and hormonal status influence the prevalence,
Caitlin Neapole +3 more
wiley +1 more source
Combinatorial use of trastuzumab and fulvestrant (CalcuSyn).
, 2017 Combinatorial use of trastuzumab and fulvestrant (CalcuSyn).
Meixin Ge (3611657) +8 more
core +1 more source
Knockdown of MED1 sensitizes breast cancer cells to fulvestrant treatment.
, 2013 (A) BT474-tet-shMED1, ZR75-1-tet-shMED1 and MCF-7-tet-shMED1 cells were treated with vehicle (-Dox) or doxycycline (+Dox) and subjected to western blot analyses using indicated antibodies.
Yongquan Li (224436) +5 more
core +1 more source
, 2016 Purpose: Resistance to endocrine therapy in estrogen receptor-positive (ER +) breast cancer remains a major clinical problem. Recently, the CDK4/6 inhibitor palbociclib combined with letrozole or fulvestrant was approved for treatment of ER + advanced ...
Ditzel, Henrik J +6 more
core +1 more source
Risposta rapida e duratura a fulvestrant in paziente con malattia metastatica e impegno viscerale
, 2012 Caso clinico che descrive una paziente in post-menopausa con diagnosi di recidiva linfonodale, polmonare e scheletrica di carcinoma duttale infiltrante a recettori estrogenici positivi, diagnosticata in corso di ormonoterapia adiuvante con inibitore non ...
Gravina, A +4 more
core